long intergenic non-protein coding RNA 1702Genealiases: []
Q-omics provides the consensus-scored LINC01702 profile across patient tissues and cancer cell-line models. LINC01702 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC01702 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC01702 RNA expression shows 8,788 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight CESC, KIRC, and LIHC as cancer lineages where LINC01702 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01702 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01702 survival associations across molecular data types. LINC01702 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01702 RNA expression–survival associations across cancer types. High LINC01702 expression shows unfavorable associations in CESC, CHOL and BRCA, but favorable associations in HNSC, KIRC and ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC01702 RNA expression.
This table summarizes LINC01702 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01702. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01702 shows lower tumor expression in KIRC, KIRP, KICH, LIHC and CHOL and higher tumor expression in LUAD. The KIRC box plot shows higher LINC01702 RNA expression in normal versus tumor tissue (log2 FC = −1.752, t-test p < 0.001).
This table shows molecular features associated with LINC01702 in patient tissues and cancer cell lines. In patient samples, LINC01702 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
